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Background: Nonalcoholic fatty liver disease (NAFLD) has emerged as the major pediatric chronic liver disease, and
it is estimated to affect more than one third of obese children in the U.S. Cardiovascular complications are a
leading cause of increased mortality in adults with NAFLD and many adolescents with NAFLD already manifest
signs of subclinical atherosclerosis including increased carotid intima-media thickness.
Methods: Volume of intrahepatic fat was assessed in 50 Hispanic-American, overweight adolescents, using
Magnetic Resonance Spectroscopy. Lipoprotein compositions were measured using Nuclear Magnetic Resonance.
Results: Plasma triglycerides (TG) (p = 0.003), TG/HDL ratio (p = 0.006), TG/apoB ratio (p = 0.011), large VLDL concentration
(p = 0.019), VLDL particle size (p = 0.012), as well as small dense LDL concentration (p = 0.026) progressively increased
across higher levels of hepatic fat severity, while large HDL concentration progressively declined (p = 0.043). This
pattern of associations remained even after controlling for gender, BMI, visceral fat, and insulin resistance.
Conclusions: Our findings suggest that increased hepatic fat is strongly associated with peripheral dyslipidemia
and the amount of fat in the liver may influence cardiovascular risk. Further studies are needed to longitudinally
monitor dyslipidemia in children with NAFLD and to examine whether the reduction of hepatic fat would
attenuate their long-term CVD risk.
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Nonalcoholic fatty liver disease (NAFLD) encompasses a
wide spectrum of related disorders including simple
steatosis, nonalcoholic steatohepatitis (NASH), and cir-
rhosis. It has become a common liver disease and affects
approximately 10-30% of the general U.S. population [1].
Furthermore, with the rapid rise of childhood obesity
[2], NAFLD is the most common cause of liver disease
in pediatric populations. Hispanic-American children are
frequently reported to have the highest prevalence of
NAFLD even after controlling for the severity of obesity
[3,4]. Individuals with NAFLD can develop end-stage
liver disease; however, the global health risk of NAFLD* Correspondence: rjin@emory.edu
1Division of Pediatric Gastroenterology, Hepatology and Nutrition, School of
Medicine, Emory University, Atlanta, GA 30322, USA
Full list of author information is available at the end of the article
© 2015 Jin et al.; licensee BioMed Central. This
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.is not confined to the liver. Cross-sectional studies in
adults demonstrate a strong association of NAFLD with
increased prevalence of clinical cardiovascular disease
(CVD) [5,6]. Prospective studies show that CVD is a
leading cause of death in adults with NAFLD, perhaps
exceeding the risk from liver-related mortality [7,8].
Many adolescents with NAFLD already have subclinical
atherosclerosis [9,10]. The growing evidence from these
recent studies strongly emphasizes the importance of
evaluating the CVD risk in pediatric NAFLD.
Lipids have been extensively investigated in NAFLD
patients and the patterns associated with insulin resist-
ance including high triglycerides (TG) and reduced
high density lipoprotein (HDL) are commonly reported
[11,12]. This alone could be responsible for the in-
creased CVD associated with NAFLD because a high
TG/HDL ratio is known to predict small dense lowis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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particle [15,16]. However, while this pattern has been
described in NAFLD, less is known about the relation-
ship of lipoprotein particle size and number to the se-
verity of NAFLD, especially in the pediatric population.
In our current study, we aimed to evaluate the lipopro-
tein particle profile in a group of overweight, Hispanic-
American adolescents who presented with a wide range
of hepatic fat as measured by state-of-the-art magnetic
resonance spectroscopy (MRS) methodology. This allowed
us to isolate the effects of hepatic fat from body mass
index (BMI) and insulin resistance which also may influ-
ence CVD risk. Here, we reported that the severity of hep-
atic fat has a strong association with a more atherogenic
phenotype of lipoproteins.
Results
Among these Hispanic-American adolescents (n = 50)
who routinely had high consumption of sugar-sweetened
beverages (SSBs), the prevalence of NAFLD (identified
as hepatic fat > 5% by MRS) was 74% (n = 37). When
stratified by the degree of intrahepatic fat, subjects with
greater quantities of liver fat had increased alanine ami-
notransferase (ALT) (p < 0.001), visceral fat (p = 0.053),
insulin (p = 0.008), and insulin resistance (indicated by
HOMA-IR and adipo-IR, p = 0.019 and p = 0.002, re-
spectively) (Table 1). The proportion of males was mark-
edly increased in the category of the highest hepatic fat
severity (p = 0.005) (Table 1).
As presented in Table 2, plasma TG (p = 0.003), TG to
HDL ratio (p = 0.006), TG to apolipoprotein (apo) B ra-
tio (p = 0.011), large very low density lipoprotein (VLDL)
concentration (p = 0.019), VLDL particle size (p = 0.012),
as well as small dense LDL concentration (p = 0.026)
progressively increased across higher levels of hepatic fatTable 1 Baseline characteristics of the study population strat
Parameters, mean (SD) Hepatic fat < 5% Hepatic
n 13 18
Age (years) 14.5 (1.85) 13.8 (2.23
Male (n, %) 5 (38.5) 3 (16.7)
Weight (kg) 82.9 (19.8) 79.6 (17.4
BMI z score 1.94 (0.26) 2.04 (0.32
ALT (U/L) 16.9 (7.27) 19.8 (8.04
Hepatic fat (%) 3.95 (0.64) 7.25 (1.63
Visceral fat (cm2) 86.6 (35.7) 71.0 (23.3
Glucose (mmol/L) 5.28 (0.89) 5.27 (0.71
Insulin (mU/L) 17.3 (7.14) 29.3 (20.6
HOMA-IR 3.94 (1.45) 7.03 (5.64
Adipo-IR 13.4 (5.40) 23.4 (20.7
hs-CRP (mg/L) 3.28 (3.47) 3.10 (2.27
P-values were generated using ANOVA or alternatively Kruskal-Wallis tests for variabseverity, while large HDL concentration progressively
declined (p = 0.043).
The relationship between hepatic fat and lipid and
lipoprotein profile was further evaluated by adjusting po-
tential confounders (Table 3). Consistently, plasma TG,
TG to HDL ratio, TG to apoB ratio, large VLDL concen-
tration, VLDL particle size, as well as small dense LDL
remained positively associated with the degree of liver
fat after adjusting for gender, BMI z-score, visceral fat,
ALT, insulin, and insulin resistance indexes (both hepatic
and adipose) (p ≤ 0.05 for all).
Furthermore, hepatic fat appeared to be specifically as-
sociated with the small dense LDL subclass, irrespective
of total LDL cholesterol, insulin resistance, and inflam-
matory status (p < 0.05) (Table 4).
Discussion
In this cross-sectional study of overweight or obese
Hispanic-American adolescents, a higher “dose” of fat in
the liver was associated with a more atherogenic dyslip-
idemia characterized by increased plasma triglycerides,
larger VLDL size, as well as greater small, dense LDL
particles. Importantly, this dyslipidemic profile associ-
ated with intrahepatic fat was independent of multiple
classical risk factors for CVD including obesity and adi-
posity, hyperinsulinemia, and insulin resistance. These
findings suggest that hepatic fat is not only a marker of
CVD risk, but also may be an important mediator in the
pathogenesis of early atherosclerosis.
Several large natural history studies have shown that
CVD is increased in adults with NAFLD [17-19].
Specifically, presence of NAFLD increases the risk
of stroke and heart attack 2 fold over the risk from meta-
bolic syndrome [17], suggesting that NAFLD pathophysi-
ology contributes something above and beyond theified by hepatic fat (%)
fat ≥ 5% and < 10% Hepatic fat ≥ 10% p-value
19
) 13.5 (2.91) 0.450
13 (68.4) 0.005
) 81.8 (13.9) 0.853
) 2.24 (0.43) 0.058
) 73.6 (111) <0.001
) 15.6 (4.85) <0.001
) 114 (48.8) 0.053
) 5.22 (1.08) 0.857
) 41.4 (35.7) 0.008
) 10.2 (11.0) 0.019
) 63.7 (126) 0.002
) 7.21 (7.95) 0.151
les with a non-normal distribution. Sex was compared by the Fisher Exact test.
Table 2 Plasma lipid and lipoprotein profiles in the entire cohort stratified by hepatic fat (%)
Parameters, mean (SD) Hepatic fat < 5% Hepatic fat ≥ 5% and < 10% Hepatic fat ≥ 10% p-value
Standard lipid profile
Cholesterol (mg/dl) 155 (21.8) 156 (31.6) 180 (50.9) 0.116
TG (mg/dl) 75.9 (26.7) 126 (71.8) 187 (117) 0.003
LDL (mg/dl) 98.5 (27.6) 102 (23.9) 117 (45.1) 0.247
HDL (mg/dl) 46.5 (8.48) 41.3 (7.75) 44.3 (9.45) 0.147
nonHDL (mg/dl) 109 (25.5) 115 (26.9) 136 (50.9) 0.113
TG/HDL ratio 1.76 (0.95) 3.16 (2.02) 4.23 (2.49) 0.006
apoB (mg/dl) 61.0 (17.9) 65.5 (16.2) 75.6 (28.7) 0.299
TG/apoB ratio 1.27 (0.37) 1.96 (0.94) 2.53 (1.65) 0.011
FFA (mEq/L) 0.81 (0.27) 0.80 (0.26) 1.15 (0.72) 0.071
Lipoprotein profile by NMR
VLDL & Chy particles (nmol/L) 44.5 (21.6) 57.7 (24.0) 56.8 (31.0) 0.202
Large VLDL & Chy 1.32 (0.64) 5.01 (5.79) 6.46 (5.61) 0.019
Medium VLDL 13.9 (10.6) 23.9 (21.6) 25.1 (18.8) 0.202
Small VLDL 29.3 (14.5) 28.7 (13.1) 25.3 (12.4) 0.633
LDL particles (nmol/L) 864 (279) 945 (211) 1136 (481) 0.084
IDL 80.0 (42.8) 73.6 (66.2) 77.9 (64.1) 0.954
Large LDL 343 (121) 320 (188) 358 (165) 0.777
Small LDL 441 (295) 552 (267) 776 (445) 0.026
HDL particles (μmol/L) 31.1 (4.37) 30.0 (3.06) 31.7 (5.25) 0.409
Large HDL 5.69 (2.42) 4.20 (1.68) 4.11 (2.37) 0.043
Medium HDL 9.57 (9.57) 10.7 (4.25) 10.3 (4.23) 0.667
Small HDL 15.8 (3.28) 15.1 (4.79) 17.3 (5.04) 0.743
VLDL size (nm) 44.8 (4.73) 49.4 (8.12) 53.1 (7.94) 0.012
LDL size (nm) 20.7 (0.58) 20.6 (0.57) 20.5 (0.50) 0.664
HDL size (nm) 9.20 (0.45) 9.01 (0.32) 8.94 (0.41) 0.178
P-values were generated using ANOVA or alternatively Kruskal-Wallis tests for variables with a non-normal distribution. Bold indicated statistical significance.
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mechanisms of the NAFLD and CVD risk are not
known but recent work demonstrated that NAFLD
is closely associated with the impairment of endo-
thelial function and morphology as well as increased
prevalence of carotid artery disease [19,20].
The liver plays a critical role in the biological process
of VLDL assembly and secretion. Both hepatic steatosis
[21,22] and insulin resistance [23] are known to be
associated with increased large VLDL concentrations.
Fabbrini et al. postulated that this alteration of VLDL
particles in NAFLD could result from a dissociation in
the regulation of the VLDL-TG and VLDL-apoB secre-
tion rate, and they demonstrated increased TG content
of newly secreted VLDL particles in NAFLD [24]. In the
setting of insulin resistance, delivery of free fatty acid
(FFA) to the liver is augmented because of the failure to
suppress lipolysis in the adipose tissue [25]. De novo
lipogenesis (DNL) is upregulated in NAFLD [26] and is
further stimulated by carbohydrate intake such as sugarsweetened beverages [27]. The combination of increased
FFA flux to the liver plus increased DNL could explain
the production of large, TG rich VLDL that occurs in
NAFLD and was demonstrated in this study.
The mechanisms linking large VLDL to small dense
LDL are not completely understood but appear to be
relevant to NAFLD CVD risk. Overproduction of TG
rich lipoprotein (TRL) activates the enzyme cholesterol
ester transfer protein (CETP) [28] leading to an increase
in the exchange of cholesterol ester and triglyceride be-
tween TRL and LDL. This CETP-mediated interaction
generates excellent substrates for further lipolysis and
clearance by hepatic lipase, promoting the formation of
small dense LDL. It is well established that small LDL
has low affinity to LDL receptors and is more susceptible
to oxidative modification, which contributes to athero-
genicity [29,30]. It is also possible that large VLDL could
be selectively retained in the arterial intima and there-
fore may share with LDL the potential for promoting
atherosclerosis [31,32].
Table 3 Relationship of the lipid and lipoprotein profiles with hepatic fat (%) as a continuous variable
Variable Model 1 Model 2
Standard Lipid Profile
Cholesterol (mg/dl) 0.006 (−0.005 – 0.017) 0.007 (−0.008 – 0.022)
TG (mg/dl) 0.053 (0.028 – 0.079)** 0.043 (0.006 – 0.081)*
LDL (mg/dl) 0.004 (−0.011 – 0.020) 0.013 (−0.010 – 0.035)
HDL (mg/dl) 0.001 (−0.009 – 0.010) −0.004 (−0.017 – 0.010)
nonHDL (mg/dl) 0.007 (−0.008 – 0.021) 0.010 (−0.011 – 0.031)
TG/HDL ratio 0.052 (0.025 – 0.080)** 0.047 (0.002 – 0.092)*
TG/apoB ratio 0.046 (0.025 – 0.067)** 0.032 (0.001 – 0.063)*
apoB (mg/dl) 0.007 (−0.008 – 0.023) 0.012 (−0.011 – 0.034)
Lipoprotein Compositions
VLDL&Chy particles (nmol/L) 0.007 (−0.017 – 0.031) 0.006 (−0.031 – 0.043)
Large VLDL & Chy 0.069 (0.022 – 0.116)* 0.077 (0.011 – 0.043)*
LDL particles (nmol/L) 0.010 (−0.007 – 0.026) 0.015 (−0.010 – 0.040)
Small LDL 0.045 (0.007 – 0.083)* 0.059 (0.003 – 0.121)*
HDL particles (μmol/L) 0.002 (−0.005 – 0.009) 0.003 (−0.007 – 0.014)
Large HDL −0.013 (−0.037 – 0.011) −0.021 (−0.059 – 0.016)
VLDL size (nm) 0.008 (0.001 – 0.155)* 0.016 (0.002 – 0.022)*
LDL size (nm) −0.001 (−0.002 – 0.001) −0.001 (−0.003 – 0.001)
HDL size (nm) −0.001 (−0.003 – 0.001) −0.002 (−0.005 – 0.001)
Model 1: Unadjusted.
Model 2: adjusted for gender, BMI z-score, ALT, visceral fat, insulin, and insulin sensitivity.
Data are expressed as β coefficient of change per one-unit change in % hepatic fat (95% confidence interval). **p < 0.001; *p < 0.05; Data were log2 transformed.
Bold indicated statistical significance.
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NAFLD and insulin resistance, it is widely believed that
hyperinsulinemia and insulin resistance are key meta-
bolic defects resulting in increased accumulation of he-
patocellular triglyceride. However, it is also possible that
primary dysregulation of lipoprotein metabolism, includ-
ing overproduction and impaired secretion of hepatic
triglycerides, could contribute to hepatic steatosis inde-
pendent of insulin resistance [33,34]. A recent multi-
ethnic study of atherosclerosis in adults [22] indicated a
strong correlation between NAFLD and the lipoprotein
derangements irrespective of insulin resistance. Here, we
furthered and expanded upon this finding in the pediatricTable 4 Beta coefficients for the association between
hepatic fat and %small dense LDL particles
Linear regression covariates * β (SEE) P value
LDL 0.308 (0.157) 0.038
LDL, Insulin resistance 0.330 (0.173) 0.043
LDL, Inflammatory indicators 0.355 (0.163) 0.023
LDL, Insulin resistance, Inflammatory indicators 0.362 (0.181) 0.035
LDL, Insulin resistance, Inflammatory indicators, 0.340 (0.186) 0.053
Sex, BMI z-score
*Insulin resistance included plasma insulin, HOMA-IR, and adipo-IR; inflammatory
indicators were ALT, hs-CRP. Data were log2 transformed when appropriate.cohort by demonstrating that the severity of liver fat in ad-
olescents was associated with increased concentrations of
large VLDL and small LDL after controlling for insulin re-
sistance indexes. This current study is important because
Hispanic-American children are one of the highest risk
groups for NAFLD and because it shows the relationship
between hepatic fat and lipoproteins is present at the earli-
est stages of disease. Further, much of the research on
NAFLD and CVD has focused on inflammation, oxidative
stress, insulin resistance and NASH [35-37]. Here, we ob-
served a “dose” effect of hepatic fat on cardiovascular risk,
primarily represented by an elevation of the atherogenic,
small LDL subfraction. This finding raises the question:
while the amount of fat in the liver does not have long
term prognosis for progression to cirrhosis, could the fat
volume be predictive of CVD and therefore could fat re-
duction be useful in decreasing CVD risk?
Large HDL particles are believed to be more anti-
atherogenic [38,39]. The lower concentration of large
HDL particles as seen in our participants who had in-
creased severity of hepatic steatosis could be indicative
of less “functional” HDL particles. HDL particles are
formed when newly secreted apoA-I interacts with ATP-
binding cassette A1 (ABCA1) on the surface of hepato-
cytes. This interaction promotes the incorporation of
phospholipids and cholesterol into the nascent HDL
Jin et al. Lipids in Health and Disease  (2015) 14:39 Page 5 of 8particles, which are crucial for accepting excess choles-
terol from peripheral tissues and lipid-laden macrophages
[40,41]. This so-termed cholesterol efflux capacity of HDL
allows for particle enlargement and plays a key role in pre-
venting carotid intima-media thickness and CVD morbid-
ity [42]. We also observed a blurred association between
the degree of liver fat and the concentration of large HDL
particles after multivariable adjustment for BMI, visceral
adiposity, and insulin resistance. It is possible that liver fat
per se might not have an independent influence on HDL
composition, or at least the contribution from hepatic fat
could be mitigated by any other factors such as visceral
adiposity [43]. It is also possible that, in the setting of in-
sulin resistance, hyperinsulinemia interrupts HDL biogen-
esis via promoting phosphorylation and degradation of
ABCA1 [44]. Our findings underscore the complexity of
HDL metabolism given its nature of heterogeneity and
constant remodeling. Carefully designed kinetic studies
will be needed in the future to accurately delineate the al-
tered metabolism of HDL in pediatric NAFLD.
There are several strengths of our study. First, MRS
methodology provides us a precise and noninvasive meas-
ure of hepatic fat. This quantitative assessment of liver fat
has shown close correlation with biopsy (r = 0.9) and is su-
perior to other traditional methods such as MRI and
Dixon imaging technique [45]. Moreover, we treated our
data as both categorical and continuous variables to re-
duce the potential error/bias introduced by grouping. By
performing linear regression models, we are able to adjust
underlying confounders and well characterize the relation-
ship between liver fat and the lipoprotein profile.
Our study is also subject to some limitations. Our find-
ings were generated from a relatively small size of a group
of Hispanic children, and they may not be generalizable to
other races/ethnic groups. Large-scaled analyses stratified
by race/ethnicity will be needed to fully explore differ-
ences in the relationship between NAFLD and lipopro-
teins. Also, we were not able to evaluate NASH and CVD
risk because our study participants did not undergo liver
biopsy. Only a few of the participants had elevated ALT
and this makes it more likely that most had steatosis with-
out substantial inflammation; however it remains un-
known. Finally, we cannot rule out the possibility that the
fasting measures of insulin resistance did not completely
capture the information of insulin sensitivity. Given the
fact that there is no single measure that can adequately
address insulin resistance, we included a series of direct
and indirect measures of insulin resistance in our regres-
sion model, such as HOMA-IR, adipo-IR, BMI, and vis-
ceral adiposity.
Conclusions
In conclusion, our findings demonstrated that among over-
weight or obese Hispanic-American adolescents, increasedvolume of hepatic fat was strongly associated with a
more atherogenic lipid profile independent of insulin re-
sistance, including increased concentration of large
VLDL, greater size of VLDL particles, as well as elevated
small dense LDL particles. This could explain early
manifestation of signs of subclinical atherosclerosis in
adolescents with NAFLD. Future studies are needed to
assess if treatments that reduce hepatic fat will also de-
crease cardiovascular risk in NAFLD.
Methods
Subjects and study design
A total of 50 Hispanic-American children (overweight,
BMI z-score ≥ 85th percentile, n = 4; and obese, BMI z-
score ≥ 95th percentile, n = 46) were recruited from
pediatric clinics at Emory Children’s Center and from
nearby community centers through flyers and presenta-
tions at community events. Eligibility criteria included
self-identification as Hispanic, ages 11–18 years; BMI ≥
85th percentile for age and gender; and average self-
reported consumption of at least 3 servings of SSBs per
day. We studied Hispanic children because of their dis-
proportionately high risk of hepatic steatosis [3,46]. High
consumption of SSBs was designed as an inclusion cri-
terion in order to increase the probability of recruiting
subjects who were likely to have significant steatosis
[46,47] but without having been previously diagnosed
and treated. Exclusion criteria included pregnancy; pre-
viously known liver diseases; diabetes or fasting glu-
cose > 126 mg/dl; renal insufficiency (creatinine > 2
mg/dl); any chronic diseases requiring daily medication;
acute illness within the past 2 weeks prior to enrollment
(defined by fever > 100.4 °F); and anti-oxidant supple-
ment/therapy within the past 4 weeks before enrollment.
This was a cross-sectional analysis of an ethnically
matched group of children at high risk of NAFLD. All
participants underwent an anthropometric assessment
and a MRS procedure for the determination of intrahe-
patic fat. Their blood samples were collected after fast-
ing overnight (at least 12 hours) for the evaluation of
lipids and the lipoprotein profile. The study protocol
was approved by both Emory University and Children’s
Healthcare of Atlanta institutional review boards and in-
formed consent (parental consent obtained for subjects <
18 years) and assent (when applicable) were obtained for
each subject prior to the study visit.
Measurements of hepatic fat and visceral adiposity
Hepatic fat was assessed by MRS using our previously
described methods [48]. Briefly, we used a rapid 15-
second acquisition technique obtained during a single
breath hold. The sequence is constructed from five
concatenated echoes using a fixed set of echo times (TE)
(12, 24, 36, 48, and 72 ms), with each echo having a
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1024 points, and 1200 Hz bandwidth. The acquisition
was repeated three times for reproducibility. Data were
exported off-line for automatic processing with in-house
software (Matlab, Mathworks, Natick, MA). Water and
lipid magnitude spectra were analyzed by determining
the area under the curve corresponding to a user-
defined frequency range surrounding the corresponding
water/lipid peaks (water peak: 4.6 ppm; lipid peak: 1.3,
2.0 ppm). The integrated magnitude signals at each TE
were fit to exponential T2 decay curves, whereby the
equilibrium signal (M0) and the relaxation rate (R2 = 1/
T2) were determined by least-squares approximation.
Using M0 for water and lipid, the T2-corrected hepatic
lipid fraction was calculated from: % Hepatic Lipid =
M0lipid/(M0lipid +M0water).
Visceral adiposity was calculated using ImageJ soft-
ware (NIH, Bethesda, DM, USA). From a 3D gradient-
echo acquisition with a 3-point Dixon reconstruction
[49], a single, “fat-only” image was isolated at the L4 ver-
tebral body. A signal threshold was set manually for each
subject such that the subcutaneous fat was completely
identified (>90% of maximum signal). This threshold
was automatically extended to the visceral region, pro-
ducing a binary mask of fat and non-fat regions. Manual
segmentation was performed to separate subcutaneous
and visceral regions by using the intra-abdominal muscle
and perineum as boundary landmarks. The vertebra was
not included in the segmented region. Visceral adiposity
was calculated from the threshold volume of the seg-
mented intra-abdominal region.
Laboratory and lipoprotein analyses
Fasting blood samples were collected into EDTA-coated
tubes and plasma was separated immediately. Plasma
samples were protected from light and transported in ice
pack to the Biomarker Core Laboratory for further pro-
cessing (within 4 hours) using AU480 chemistry analyzer
(Beckman Coulter, Inc.). Total cholesterol and TG were
measured by enzymatic methods using reagents from
Beckman (Beckman Diagnostics, Fullerton, CA). LDL
cholesterol and HDL cholesterol were measured by
homogeneous enzymatic assays (Sekisui Diagnostics,
Exton, PA). Plasma levels of glucose, insulin, apoB,
and high sensitivity C-reactive protein (hs-CRP) were
determined using immunoturbidometric methods (Sekisui
Diagnostics, Exton, PA). Liver enzyme ALT was measured
by the Emory University Hospital clinical laboratory.
Lipoprotein particle concentrations and sizes were
measured by NMR spectroscopy using a 400-MHz NMR
clinical analyzer and the LP3 deconvolution algorithm
(LipoScience Inc., Raleigh, NC) [50]. In brief, the NMR
method uses the characteristic signals broadcast by lipo-
protein subclasses of different size as the basis of theirquantification. Each lipoprotein subclass signal emanates
from the aggregate number of methyl groups on the
lipids contained within the particle. This number is
largely dependent on lipoprotein particle diameter and
independent of lipid composition; thus, the amplitude of
each lipoprotein subclass signal is directly proportional
to the number of subclass particles emitting the signal.
The subgroup of large VLDL and chylomicron particles
were not able to be differentiated by this NMR tech-
nique, and in the current study, this subgroup was con-
sidered mainly as large VLDL because samples were
obtained in a fasting state.
Indexes of insulin resistance
Insulin sensitivity was assessed by the homeostasis model
of assessment - insulin resistance (HOMA-IR) and the
newly defined index adipo-IR [51]. HOMA-IR was calcu-
lated by glucose (mmol/L) × insulin (mU/L) / 22.5 at the
fasting state, and adipo-IR was calculated by fasting FFA
(mEq/L) × insulin (mU/L).
Statistical analyses
We treated “hepatic fat” as both a categorical and a con-
tinuous variable. Demographic, anthropometric, and
metabolic parameters of the study population were com-
pared across stratifications of hepatic fat using ANOVA
or alternatively Kruskal-Wallis tests for variables with a
non-normal distribution. Sex was compared by the
Fisher Exact test. Linear regression models (unadjusted
and adjusted) were used to further assess the relation-
ship between hepatic fat and two sets of lipid parame-
ters: 1) a standard lipid profile, and 2) an advanced
lipoprotein profile by NMR. When appropriate, log
transformations were used to normalize outcome vari-
ables with skewed distributions. Statistical analysis was
performed using SAS (version 9.3, Cary, NC).
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